Although various strategies modify the transition from infection to life-threatening forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines remain highly effective measures to curb the pandemic [1]. SARS-CoV-2 vaccines approved by the European Medical Agency (EMA) elicit an immune neutralizing response [2] and demonstrated an excellent safety/efficacy profile in Phase III vaccine trials [1,3].
